Visit KQAK 105.7
Visit The Peak 104.1
Visit 95.7 The Ranch
Visit 92.5 The Ticket
Visit KBNW 104.5AM AND 1340AM
Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

2.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
Before 10 a.m. ET on Friday, 43 companies set new 52-week lows. Points of Interest: Autohome (NYSE:ATHM) was the largest firm by market cap to set a new 52-week low... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
During Wednesday's morning session, 29 stocks hit new 52-week lows. Points of Interest: The largest company by market cap to set a new 52-week low was CoStar Gr (... 
Via Benzinga
News headline image
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
Immunoprecise Share Are Trading Higher On Encouraging Preclinical Data Of COVID-19 Antibody Cocktail ↗
Immunoprecise Antibodies Ltd (NASDAQ: IPA) has announced additional results from its in vivo hamster challenge efficacy study of TATX-03a PolyTope Therapy, a four... 
Via Benzinga
News headline image
Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 32.67% to $67.0 during Friday's pre-market session. The company's market cap stands at $860.7... 
Via Benzinga
News headline image
ImmunoPrecise Launches TATX-112 Antibody Program For Cancer, Alzheimer's Disease ↗
ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary Talem Therapeutics LLC has advanced developing a candidate referred to as TATX-112,... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers 180 Life Sciences (NASDAQ:ATNF) stock increased by 25.09% to $9.92 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
News headline image
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
From ImmunoPrecise Antibodies
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.